Epoxomicin, a new antitumor agent of microbial origin.
An actinomycete strain No. Q996-17 produced a novel compound, epoxomicin, which exhibited in vivo antitumor activity against B16 melanoma. Structural studies indicated that it is a new member of the epoxy-beta-aminoketone group, and is closely related to eponemycin.
Hanada
M
M
Bristol-Myers Squibb Research Institute, Tokyo, Japan.
Sugawara
K
K
Kaneta
K
K
Toda
S
S
Nishiyama
Y
Y
Tomita
K
K
Yamamoto
H
H
Konishi
M
M
Oki
T
T
D000192:Actinomycetales / Q000378:metabolism*; D000577:Amides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000737:chemistry / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000096:biosynthesis / Q000737:chemistry / Q000627:therapeutic use; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D005285:Fermentation; D009682:Magnetic Resonance Spectroscopy; D008546:Melanoma, Experimental / Q000188:drug therapy; D015394:Molecular Structure; D009842:Oligopeptides; D012694:Serine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013053:Spectrophotometry
D000577:Amides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D009842:Oligopeptides; C063282:eponemycin; D012694:Serine; C078846:epoxomicin